

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 12610-0020US1	Application No. 10/578,561
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Howard J. Federoff et al.	
		Filing Date March 1, 2007	Group Art Unit 1649

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
------------------	-----------	-----------------	------------------	----------	-------	----------	----------------------------

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes      No
------------------	-----------	-----------------	------------------	--------------------------	-------	----------	----------------------------

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	1	Holscher et al., "Overexpression of nonconvertible PrP <sup>C</sup> Δ114-121 in scrapie-infected mouse neuroblastoma cells leads to trans-dominant inhibition of wild type PrP <sup>Sc</sup> accumulation," J. Virol. 72(2):1153-9 (1998).
	2	Yant et al., "Somatic integration and long term transgene expression in normal and haemophilia mice using a DNA transposon system," Nat. Gen. 25:35-41 (2000).
	3	
	4	

Examiner Signature  /Robert Kelly/ (07/27/2009)	Date Considered  /Robert Kelly/ (07/27/2009)
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RMK/